Literature DB >> 21917763

Age and disability accumulation in multiple sclerosis.

A Scalfari1, A Neuhaus, M Daumer, G C Ebers, P A Muraro.   

Abstract

OBJECTIVES: We tested the hypothesis that age is a prognostic factor with respect to long-term accumulation of disability in multiple sclerosis (MS).
METHODS: Kaplan-Meier analysis and binary logistic regression models determined the effect of age at disease onset, age at onset of progression, and current age on attainment of severe disability levels (Disability Status Scale [DSS] 6-8-10) from the London, Ontario, database (n = 1,023).
RESULTS: Older age at relapsing-remitting (RR) phase onset was associated with higher risk of reaching advanced DSS scores. This was independent of disease duration and early relapse frequency but secondary to increased risk of conversion to secondary progressive (SP) MS. Onset at age 40 (odds ratio [OR] = 4.22) and at age 50 (OR = 6.04) doubled and tripled risks of developing SP, compared to age 20 (OR = 2.05). Younger age at conversion to SPMS was associated with shorter times to high DSS scores from disease onset. The progressive course, unaffected by age at RR onset, was only modestly affected by age at SP onset. Among primary progressive and RR/SP patients, median ages at attainment of DSS scores were strikingly similar: DSS = 6, 49 vs 48 years; DSS = 8, 58 vs 58 years; and DSS = 10, 78 years for both (p = NS for all comparisons).
CONCLUSIONS: Development of SP is the dominant determinant of long-term prognosis, independent of disease duration and early relapse frequency. Age independently affects disability development primarily by changing probability and latency of SP onset, with little effect on the progressive course.

Entities:  

Mesh:

Year:  2011        PMID: 21917763      PMCID: PMC3179646          DOI: 10.1212/WNL.0b013e318230a17d

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

Authors:  Christian Confavreux; Sandra Vukusic; Patrice Adeleine
Journal:  Brain       Date:  2003-04       Impact factor: 13.501

2.  Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis.

Authors:  J G Phadke
Journal:  Brain       Date:  1990-12       Impact factor: 13.501

3.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

Authors:  B G Weinshenker; G P Rice; J H Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

4.  Early prognostic factors for disability in multiple sclerosis, a European multicenter study.

Authors:  T Riise; M Grønning; O Fernández; K Lauer; R Midgard; J M Minderhoud; H Nyland; G Pálffy; S Poser; J A Aarli
Journal:  Acta Neurol Scand       Date:  1992-03       Impact factor: 3.209

5.  Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada.

Authors:  W J Hader; M Elliot; G C Ebers
Journal:  Neurology       Date:  1988-04       Impact factor: 9.910

6.  The course of multiple sclerosis in 73 cases with computer-designed curves.

Authors:  T Fog; F Linnemann
Journal:  Acta Neurol Scand Suppl       Date:  1970

7.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

8.  Age at onset, initial symptomatology and the course of multiple sclerosis.

Authors:  S Poser; N E Raun; W Poser
Journal:  Acta Neurol Scand       Date:  1982-09       Impact factor: 3.209

9.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

10.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

Authors:  C Confavreux; G Aimard; M Devic
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

View more
  63 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

2.  Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis.

Authors:  Claudia Mara Ribeiro; Sayonara Rangel Oliveira; Daniela Frizon Alfieri; Tamires Flauzino; Damacio Ramón Kaimen-Maciel; Andréa Name Colado Simão; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Inflamm Res       Date:  2019-09-26       Impact factor: 4.575

3.  Early predictive factors of disability in CIDP.

Authors:  Emanuele Spina; Antonietta Topa; Rosa Iodice; Stefano Tozza; Lucia Ruggiero; Raffaele Dubbioso; Marcello Esposito; Dario Bruzzese; Lucio Santoro; Fiore Manganelli
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

4.  Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Authors:  Melih Tutuncu; Junger Tang; Nuhad Abou Zeid; Nilufer Kale; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; Sean J Pittock; Istvan Pirko; B Mark Keegan; Claudia F Lucchinetti; John H Noseworthy; Moses Rodriguez; Brian G Weinshenker; Orhun H Kantarci
Journal:  Mult Scler       Date:  2012-06-26       Impact factor: 6.312

5.  Telomere Length Is Associated with Disability Progression in Multiple Sclerosis.

Authors:  Kristen M Krysko; Roland G Henry; Bruce A C Cree; Jue Lin; Stacy Caillier; Adam Santaniello; Chao Zhao; Refujia Gomez; Carolyn Bevan; Dana L Smith; William Stern; Gina Kirkish; Stephen L Hauser; Jorge R Oksenberg; Jennifer S Graves
Journal:  Ann Neurol       Date:  2019-10-02       Impact factor: 10.422

Review 6.  Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.

Authors:  Afsaneh Shirani; Darin T Okuda; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 7.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

Review 8.  Exercise as Medicine in Multiple Sclerosis-Time for a Paradigm Shift: Preventive, Symptomatic, and Disease-Modifying Aspects and Perspectives.

Authors:  Ulrik Dalgas; Martin Langeskov-Christensen; Egon Stenager; Morten Riemenschneider; Lars G Hvid
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

Review 9.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

10.  ATP7B variants as modulators of copper dyshomeostasis in Alzheimer's disease.

Authors:  Rosanna Squitti; Renato Polimanti; Mariacristina Siotto; Serena Bucossi; Mariacarla Ventriglia; Stefania Mariani; Fabrizio Vernieri; Federica Scrascia; Laura Trotta; Paolo Maria Rossini
Journal:  Neuromolecular Med       Date:  2013-06-13       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.